← All trials
NCT03468465
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 4, 2018
- Primary completion
- Mar 31, 2019
- Completion date
- Mar 31, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 110
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Fundacion para la Formacion e Investigacion Sanitarias de la Region de MurciaLead sponsor
- Hospital Clínica Universitario Virgen de la Arrixaca (SPAIN)Overall official - principal investigator
- Hospital Clínico Universitario San Juan (SPAIN)Overall official - principal investigator
- Universidad de CordobaOverall official - principal investigator
- Hospital Rafael Méndez (Lorca, Murcia. SPAIN)Overall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.